This was a phase 2 , open-label , randomized trial of EMD 1201081 0.32 mg/kg subcutaneously weekly plus cetuximab ( combination ) vs cetuximab monotherapy ( control ) in cetuximab-nave patients with R/M SCCHN who progressed on 1 cytotoxic regimen .